$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000141057822000232 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$56.44M	$56.69M	$222.6M
YoY Change	16.71%	407.46%	182.87%
Cost Of Revenue	$33.33M	$33.18M	$126.0M
YoY Change	17.06%	548.43%	197.51%
Gross Profit	$23.11M	$23.51M	$96.58M
YoY Change	16.18%	288.32%	165.8%
Gross Profit Margin	40.95%	41.47%	43.38%
Selling, General & Admin	$27.59M	$23.90M	$97.56M
YoY Change	5.09%	65.11%	71.58%
% of Gross Profit	119.35%	101.65%	101.02%
Research & Development	$3.890M	$4.188M	$16.84M
YoY Change	11.46%	81.14%	77.59%
% of Gross Profit	16.83%	17.81%	17.44%
Depreciation & Amortization	$5.303M	$5.157M	$20.25M
YoY Change	-28.05%	521.33%	105.16%
% of Gross Profit	22.94%	21.93%	20.96%
Operating Expenses	$31.48M	$28.09M	$114.4M
YoY Change	5.84%	67.32%	72.44%
Operating Profit	-$8.362M	-$4.576M	-$17.83M
YoY Change	-15.08%	-57.36%	-40.59%
Interest Expense	$509.0K	$1.189M	$4.689M
YoY Change	-259.06%	-37.06%	83.16%
% of Operating Profit
Other Income/Expense, Net	-$1.354M	-$926.0K	-$256.0M
YoY Change	-7.89%	29.69%	9284.64%
Pretax Income	-$261.0M	-$5.502M	-$273.8M
YoY Change	2143.87%	-51.94%	736.47%
Income Tax	-$876.0K	$1.024M	$1.686M
% Of Pretax Income
Net Earnings	-$260.1M	-$6.526M	-$275.5M
YoY Change	2155.73%	-42.84%	742.77%
Net Earnings / Revenue	-460.82%	-11.51%	-123.77%
Basic Earnings Per Share	-$5.46	-$0.18	-$6.18
Diluted Earnings Per Share	-$5.413M	-$0.17	-$6.19
COMMON SHARES
Basic Shares Outstanding	46.30M	46.14M	45.93M
Diluted Shares Outstanding		46.14M	45.93M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$628.8M	$349.5M	$628.8M
YoY Change	573.95%	72.24%	573.95%
Cash & Equivalents	$139.1M	$43.68M	$111.3M
Short-Term Investments	$601.0M	$305.8M	$601.0M
Other Short-Term Assets	$8.804M	$8.958M	$8.804M
YoY Change	-26.02%	539.86%	-26.02%
Inventory	$16.50M	$13.48M	$16.50M
Prepaid Expenses
Receivables	$39.41M	$38.46M	$39.41M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$693.5M	$410.4M	$693.5M
YoY Change	371.28%	92.99%	371.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$49.03M	$42.85M	$69.70M
YoY Change	63.23%	182.32%	58.06%
Goodwill	$147.0M	$146.4M
YoY Change	1.15%	1230.65%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$419.0K	$158.0K	$1.369M
YoY Change	-47.23%	-68.4%	-31.55%
Total Long-Term Assets	$419.5M	$414.0M	$419.5M
YoY Change	3.51%	942.32%	3.52%
TOTAL ASSETS
Total Short-Term Assets	$693.5M	$410.4M	$693.5M
Total Long-Term Assets	$419.5M	$414.0M	$419.5M
Total Assets	$1.113B	$824.4M	$1.113B
YoY Change	101.48%	226.67%	101.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$28.58M	$29.24M	$28.58M
YoY Change	15.25%	201.39%	15.25%
Accrued Expenses	$13.45M	$11.47M	$13.45M
YoY Change	38.7%	258.41%	38.7%
Deferred Revenue	$547.0K	$308.0K
YoY Change	22.92%	29.97%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$61.00K	$61.00K	$61.00K
YoY Change	-39.0%	-39.0%	-39.0%
Total Short-Term Liabilities	$42.65M	$41.07M	$42.65M
YoY Change	21.77%	211.5%	21.84%
LONG-TERM LIABILITIES
Long-Term Debt	$405.3M	$116.5M	$405.3M
YoY Change	248.2%	4.67%	248.2%
Other Long-Term Liabilities	$349.0K	$148.0K	$19.17M
YoY Change	98.3%	-98.1%	54.6%
Total Long-Term Liabilities	$349.0K	$148.0K	$424.5M
YoY Change	98.3%	-99.88%	229.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.65M	$41.07M	$42.65M
Total Long-Term Liabilities	$349.0K	$148.0K	$424.5M
Total Liabilities	$471.1M	$177.2M	$471.1M
YoY Change	177.62%	33.88%	177.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$467.5M	-$207.5M
YoY Change	143.49%	14.94%
Common Stock	$1.100B	$846.2M
YoY Change	94.24%	181.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$641.8M	$647.2M	$641.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.113B	$824.4M	$1.113B
YoY Change	101.48%	226.67%	101.48%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	-$260.1M	-$6.526M	-$275.5M
YoY Change	2155.73%	-42.84%	742.77%
Depreciation, Depletion And Amortization	$5.303M	$5.157M	$20.25M
YoY Change	-28.05%	521.33%	105.16%
Cash From Operating Activities	$2.614M	$8.876M	$8.126M
YoY Change	-126.89%	-283.39%	-154.66%
INVESTING ACTIVITIES
Capital Expenditures	-$8.544M	-$9.200M	$23.88M
YoY Change	92.87%	251.15%	167.8%
Acquisitions			$5.540M
YoY Change			-98.47%
Other Investing Activities	-$187.4M	-$17.81M	-$444.2M
YoY Change	-50.5%	-114.48%	19.22%
Cash From Investing Activities	-$196.0M	-$27.01M	-$469.3M
YoY Change	-48.84%	-122.44%	22.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	288.6M	2.491M	564.3M
YoY Change	8.3%	15.86%	46.36%
NET CHANGE
Cash From Operating Activities	2.614M	8.876M	8.126M
Cash From Investing Activities	-196.0M	-27.01M	-469.3M
Cash From Financing Activities	288.6M	2.491M	564.3M
Net Change In Cash	95.22M	-15.64M	102.2M
YoY Change	-175.37%	-113.29%	-1086.57%
FREE CASH FLOW
Cash From Operating Activities	$2.614M	$8.876M	$8.126M
Capital Expenditures	-$8.544M	-$9.200M	$23.88M
Free Cash Flow	$11.16M	$18.08M	-$15.76M
YoY Change	-310.93%	-914.23%	-33.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-34632
CY2021	dei	Entity Registrant Name EntityRegistrantName	CRYOPORT, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0313393
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45927591
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38582432
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	112 Westwood Place
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Brentwood
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45927591
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38582432
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33394285
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.19
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.19
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37027
CY2021	dei	City Area Code CityAreaCode	949
CY2021	dei	Local Phone Number LocalPhoneNumber	470-2300
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2021	dei	Trading Symbol TradingSymbol	CYRX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1900000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49694787
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Irvine
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139101000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36873000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	489698000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	56444000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1200000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1100000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39412000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	31377000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16501000
CY2020Q4	us-gaap	Inventory Net InventoryNet	10535000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8804000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11928000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	693516000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	147157000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49029000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30036000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20675000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14044000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	201427000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	213908000
CY2021Q4	us-gaap	Goodwill Goodwill	146954000
CY2020Q4	us-gaap	Goodwill Goodwill	145282000
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	950000
CY2020Q4	us-gaap	Deposits Assets DepositsAssets	1184000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	419000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	794000
CY2021Q4	us-gaap	Assets Assets	1112970000
CY2020Q4	us-gaap	Assets Assets	552405000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28583000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24844000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9912000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7441000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	547000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	445000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3542000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2231000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	61000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	59000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	42645000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35020000
CY2021	cyrx	Convertible Subordinated Debt Discount ConvertibleSubordinatedDebtDiscount	12700000
CY2020	cyrx	Convertible Subordinated Debt Discount ConvertibleSubordinatedDebtDiscount	3700000
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	404171000
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	111344000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	50000.00
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	0
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18144000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12261000
CY2021Q4	us-gaap	Liabilities Liabilities	471142000
CY2020Q4	us-gaap	Liabilities Liabilities	169707000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1086000
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4912000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49616154
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49616154
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	51000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	112000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4018000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5882000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	298000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	176000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	729000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39837058
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39837058
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	50000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	40000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1100287000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	566451000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467541000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-192013000
CY2021Q4	cyrx	Accumulated Other Comprehensive Income Loss AccumulatedOtherComprehensiveIncomeLoss	-1243000
CY2020Q4	cyrx	Accumulated Other Comprehensive Income Loss AccumulatedOtherComprehensiveIncomeLoss	5376000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	641828000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	382698000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1112970000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	552405000
CY2021	us-gaap	Revenues Revenues	222608000
CY2020	us-gaap	Revenues Revenues	78696000
CY2019	us-gaap	Revenues Revenues	33942000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	126031000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	42362000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	16590000
CY2021	us-gaap	Gross Profit GrossProfit	96577000
CY2020	us-gaap	Gross Profit GrossProfit	36334000
CY2019	us-gaap	Gross Profit GrossProfit	17352000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	97563000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56860000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31286000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16843000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9484000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3741000
CY2021	us-gaap	Operating Expenses OperatingExpenses	114406000
CY2020	us-gaap	Operating Expenses OperatingExpenses	66344000
CY2019	us-gaap	Operating Expenses OperatingExpenses	35027000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-17829000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-30010000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-17675000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	3253000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	761000
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	583000
CY2021	us-gaap	Interest Expense InterestExpense	4689000
CY2020	us-gaap	Interest Expense InterestExpense	2560000
CY2019	us-gaap	Interest Expense InterestExpense	1367000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-251754000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2823000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-929000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	189000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-256013000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2728000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-595000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-273842000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32738000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18270000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-45000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-18332000
CY2020	cyrx	Deemed Dividend On Series C Convertible Preferred Stock Value DeemedDividendOnSeriesCConvertiblePreferredStockValue	39492000
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8196000
CY2020	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	2844000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-283724000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75029000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18332000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.18
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45927591
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38582432
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33394285
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-18332000
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	3958000
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-161000
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	27000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	3000
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	23000
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	28000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2634000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5263000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6619000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5421000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-48000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-282147000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27272000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18380000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38547000
CY2019	us-gaap	Profit Loss ProfitLoss	-18332000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-48000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6871000
CY2019	cyrx	Adjustments To Additional Paid In Capital Accelerated Share Based Compensation Expense AdjustmentsToAdditionalPaidInCapitalAcceleratedShareBasedCompensationExpense	9562000
CY2019	cyrx	Stock Issued During Period Value On Net Public Offer StockIssuedDuringPeriodValueOnNetPublicOffer	68810000
CY2019	cyrx	Issuance Of Common Stock For Convertible Debt And Accrued Interest IssuanceOfCommonStockForConvertibleDebtAndAccruedInterest	15417000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	91000
CY2019	cyrx	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	5363000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	126281000
CY2020	us-gaap	Profit Loss ProfitLoss	-32693000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5421000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8833000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	83000
CY2020	cyrx	Adjustments To Additional Paid In Capital Conversion Costs AdjustmentsToAdditionalPaidInCapitalConversionCosts	237225000
CY2020	cyrx	Beneficial Conversion Feature Of Series C Convertible Preferred Stock Value BeneficialConversionFeatureOfSeriesCConvertiblePreferredStockValue	0
CY2020	cyrx	Adjustments To Additional Paid In Capital Deemed Dividend AdjustmentsToAdditionalPaidInCapitalDeemedDividend	0
CY2020	cyrx	Adjustments To Additional Paid In Capital Paid In Kind Dividends AdjustmentsToAdditionalPaidInCapitalPaidInKindDividends	0
CY2020	cyrx	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	9388000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	382698000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	382698000
CY2021	us-gaap	Profit Loss ProfitLoss	-275528000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6619000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15334000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000
CY2021	cyrx	Adjustments To Additional Paid In Capital Conversion Costs AdjustmentsToAdditionalPaidInCapitalConversionCosts	-1800000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	269825000
CY2021	cyrx	Issuance Of Common Stock For Convertible Debt And Accrued Interest IssuanceOfCommonStockForConvertibleDebtAndAccruedInterest	248911000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0
CY2021	cyrx	Adjustments To Additional Paid In Capital Paid In Kind Dividends AdjustmentsToAdditionalPaidInCapitalPaidInKindDividends	0
CY2021	cyrx	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	8996000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	641828000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-18332000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-251754000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20247000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9869000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2415000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1236000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	437000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	288000
CY2020	cyrx	Interest Cost On Convertible Note Settled By Issuance Of Common Stock InterestCostOnConvertibleNoteSettledByIssuanceOfCommonStock	0
CY2019	cyrx	Interest Cost On Convertible Note Settled By Issuance Of Common Stock InterestCostOnConvertibleNoteSettledByIssuanceOfCommonStock	418000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1386000
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	845000
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-102000
CY2020	cyrx	Realized Loss On Investments In Equity Securities RealizedLossOnInvestmentsInEquitySecurities	1090000
CY2019	cyrx	Realized Loss On Investments In Equity Securities RealizedLossOnInvestmentsInEquitySecurities	0
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-81000
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-32000
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	82000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15345000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8916000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6962000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	9562000
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-542000
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-384000
CY2019	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-274000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	26000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	197000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	42000
CY2021	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	7270000
CY2020	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	2617000
CY2019	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	3596000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5979000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1322000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	253000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3056000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7520000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	345000
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-211000
CY2020	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	152000
CY2019	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	86000
CY2021	cyrx	Right Of Use Asset Obtained In Exchange For Operating Leases Liability RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability	-562000
CY2020	cyrx	Right Of Use Asset Obtained In Exchange For Operating Leases Liability RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability	-134000
CY2019	cyrx	Right Of Use Asset Obtained In Exchange For Operating Leases Liability RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability	6000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-398000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4245000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	570000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2522000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3143000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	641000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	102000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-309000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23882000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	81000
CY2021	cyrx	Net Deferred Tax Expense Income NetDeferredTaxExpenseIncome	231000
CY2020	cyrx	Net Deferred Tax Expense Income NetDeferredTaxExpenseIncome	-499000
CY2019	cyrx	Net Deferred Tax Expense Income NetDeferredTaxExpenseIncome	21000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8126000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14866000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1324000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47235000
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	158736000
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	43196000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8918000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5336000
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	482707000
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	44000000
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	149233000
CY2019	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5995000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	255000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	73000
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	870000
CY2020	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	551000
CY2019	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	0
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5540000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	363140000
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	20317000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-469254000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-382312000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-62927000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8995000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9388000
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5363000
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	248911000
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	237225000
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28160000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	269825000
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	68811000
CY2021	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	60000
CY2020	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	70000
CY2019	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	23000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3397000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	40068000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	115000000
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4118000
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	564342000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	385585000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74151000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-986000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1231000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102228000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10362000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9908000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36873000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q2	cyrx	Statutory Credit Usage Limit For Research And Development For Tax Relief StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief	5000000
CY2021Q1	cyrx	Executive Compensation Limit ExecutiveCompensationLimit	1000000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37327000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139101000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36873000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47235000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3297000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1823000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	707000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1315000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	60000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	14000
CY2021	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	3958000
CY2020	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	161000
CY2019	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	-28000
CY2021	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	27000
CY2020	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	3000
CY2019	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	23000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1412000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	499000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	261000
CY2020	cyrx	Purchase Of Equipment Through Capital Lease Obligation PurchaseOfEquipmentThroughCapitalLeaseObligation	205000
CY2019	cyrx	Purchase Of Equipment Through Capital Lease Obligation PurchaseOfEquipmentThroughCapitalLeaseObligation	0
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stocks Value PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue	8196000
CY2020	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stocks Value PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue	2844000
CY2019	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stocks Value PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue	0
CY2021	cyrx	Common Stock Issued For Conversion Of Debt And Accrued Interest CommonStockIssuedForConversionOfDebtAndAccruedInterest	765000
CY2020	cyrx	Common Stock Issued For Conversion Of Debt And Accrued Interest CommonStockIssuedForConversionOfDebtAndAccruedInterest	0
CY2019	cyrx	Common Stock Issued For Conversion Of Debt And Accrued Interest CommonStockIssuedForConversionOfDebtAndAccruedInterest	15418000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Cryoport, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1. Nature of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport serves the life sciences industry as a provider of integrated temperature-controlled supply-chain solutions supporting the biopharma/pharma, animal health, and reproductive medicine markets. Our mission is to support life and health worldwide and we are continuously developing, implementing, and leveraging our supply chain platform, which is designed to deliver comprehensive, unparalleled, highly differentiated temperature-controlled logistics, packaging, storage, cryogenic systems, informatics, and related services for life science products, regenerative medicine, cellular therapies, and treatments that require unique, specialized cold chain management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 1, 2020, the Company completed both the MVE Acquisition and the CRYOPDP Acquisition. In addition, in the second quarter of 2021, the Company completed the acquisitions of Critical Transport Solutions Australia (CTSA) in Australia and F-airGate in Belgium to further enhance CRYOPDP’s existing global temperature-controlled supply chain capabilities in the APAC and EMEA regions. These acquisitions are further discussed in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</p>
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, allowance for inventory obsolescence, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p>
CY2021	us-gaap	Revenue Practical Expedient Initial Application And Transition Nondisclosure Of Transaction Price Allocation To Remaining Performance Obligation RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation	true
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	500000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	200000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	500000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	400000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2021 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1200000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1100000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2020	us-gaap	Revenues Revenues	78696000
CY2019	us-gaap	Revenues Revenues	33942000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	300000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	400000
CY2021	us-gaap	Revenues Revenues	222608000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-18332000
CY2020	cyrx	Deemed Dividend On Series C Convertible Preferred Stock Value DeemedDividendOnSeriesCConvertiblePreferredStockValue	39492000
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8196000
CY2020	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	2844000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-283724000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75029000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18332000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45927591
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38582432
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33394285
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.18
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11820000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139101000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36873000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	489698000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	56444000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15290040
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17205023
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4390017
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2600000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5200000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation. These reclassifications had no effect on the previously reported net loss.</p>
CY2021	cyrx	Business Combination Prior Period Adjustment Deferred Tax BusinessCombinationPriorPeriodAdjustmentDeferredTax	800000
CY2021Q4	us-gaap	Cash Cash	27788000
CY2020Q4	us-gaap	Cash Cash	25053000
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	111313000
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	93317000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	383547000
CY2021Q4	cyrx	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax1 AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax1	12000
CY2021	us-gaap	Debt And Equity Securities Realized Gain Loss Excluding Other Than Temporary Impairment DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment	80000.00
CY2020	us-gaap	Debt And Equity Securities Realized Gain Loss Excluding Other Than Temporary Impairment DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment	30000.00
CY2019	us-gaap	Debt And Equity Securities Realized Gain Loss Excluding Other Than Temporary Impairment DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment	80000.00
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	110000000.0
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	33100000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	628799000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	39081000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	39035000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	344466000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	340657000
CY2021Q4	cyrx	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax1 AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax1	3867000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	379692000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	383547000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	379692000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	23179000
CY2020Q4	cyrx	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax1 AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax1	173000
CY2020Q4	cyrx	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax1 AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax1	43000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	23309000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-1386000
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-245000
CY2019	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-102000
CY2020	cyrx	Equity Securities Realized Gain Loss Sold EquitySecuritiesRealizedGainLossSold	1090000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1386000
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	845000
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-102000
CY2021	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2
CY2021Q4	cyrx	Business Combination Contingent Consideration Liability Fair Value Disclosure BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure	700000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2204000
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2727000
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	2384000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	11846000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7544000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	670000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	227000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3985000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2764000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16501000
CY2020Q4	us-gaap	Inventory Net InventoryNet	10535000
CY2020Q4	cyrx	Inventory Related To Acquisition InventoryRelatedToAcquisition	800000
CY2021Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	9343000
CY2020Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	7442000
CY2021Q4	cyrx	Freezers Gross FreezersGross	5341000
CY2020Q4	cyrx	Freezers Gross FreezersGross	3723000
CY2020Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	300000
CY2019Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	100000
CY2020Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	4599000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	100000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	100000
CY2020Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1469000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12405000
CY2020Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	10931000
CY2021Q4	cyrx	Trucks And Autos Gross TrucksAndAutosGross	497000
CY2020Q4	cyrx	Trucks And Autos Gross TrucksAndAutosGross	437000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	21657000
CY2021Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	5808000
CY2020Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	5359000
CY2021Q4	us-gaap	Land Land	806000
CY2020Q4	us-gaap	Land Land	790000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	8583000
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	8070000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	69028000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45547000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19999000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15511000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49029000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30036000
CY2021	us-gaap	Depreciation Depreciation	5800000
CY2020	us-gaap	Depreciation Depreciation	3200000
CY2019	us-gaap	Depreciation Depreciation	2100000
CY2021Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	300000
CY2020Q4	us-gaap	Goodwill Goodwill	145282000
CY2019Q4	us-gaap	Goodwill Goodwill	11000000
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-419000
CY2021Q4	us-gaap	Goodwill Goodwill	146954000
CY2020Q4	us-gaap	Goodwill Goodwill	145282000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	224839000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23412000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	201427000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	221642000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	57000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2299000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	61000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2033000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1757000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3349000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7734000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	213908000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14400000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6600000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	14969000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	14969000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14340000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	12266000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	12118000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	88331000
CY2021Q4	cyrx	Future Amortization Of Finite Lived Intangible Assets FutureAmortizationOfFiniteLivedIntangibleAssets	156993000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8003000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6048000
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1909000
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1393000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9912000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7441000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	14035000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25795000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	118000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1005000
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2108000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3419000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	6000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21686000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	112000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3542000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	61000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18144000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	51000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21686000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	112000
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	12673000
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3656000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	404171000
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	111344000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	437000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	4424000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	2545000
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	117.59
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000
CY2021Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2021	cyrx	Lessee Option To Extend LesseeOptionToExtend	P5Y
CY2021Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	300000
CY2020Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	300000
CY2021	cyrx	Finance Lease Rightofuse Asset Accumulated Depreciation FinanceLeaseRightofuseAssetAccumulatedDepreciation	100000
CY2020	cyrx	Finance Lease Rightofuse Asset Accumulated Depreciation FinanceLeaseRightofuseAssetAccumulatedDepreciation	100000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4109000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4556000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1835000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	758000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	61000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	56000
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	8000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000
CY2021	cyrx	Finance Lease Cost FinanceLeaseCost	69000
CY2020	cyrx	Finance Lease Cost FinanceLeaseCost	66000
CY2019	cyrx	Finance Lease Cost FinanceLeaseCost	13000
CY2021	us-gaap	Lease Cost LeaseCost	4625000
CY2020	us-gaap	Lease Cost LeaseCost	1901000
CY2019	us-gaap	Lease Cost LeaseCost	771000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3993000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1680000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	760000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	65000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	77000
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	58000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	67000
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	23000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10175000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10708000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3165000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	230000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.054
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2322000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11500
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Dividends Paidinkind DividendsPaidinkind	8200000
CY2020	us-gaap	Dividends Paidinkind DividendsPaidinkind	2800000
CY2020Q4	cyrx	Deemed Dividend DeemedDividend	39500000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15.0
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4312500
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	17.00
CY2019Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	562500
CY2019Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	68800000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16868029
CY2019	cyrx	Stockissuedduringperiodsharescashlessexerciseofwarrants Stockissuedduringperiodsharescashlessexerciseofwarrants	117663
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	159583
CY2021	cyrx	Warrants Exercised Intrinsic Value WarrantsExercisedIntrinsicValue	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.706
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.992
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	cyrx	Warrants Exercised Intrinsic Value WarrantsExercisedIntrinsicValue	17600000
CY2019	cyrx	Warrants Exercised Intrinsic Value WarrantsExercisedIntrinsicValue	12400000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0047
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0118
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0031
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0170
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0257
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.644
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.808
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.698
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.827
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15345000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8916000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	16523000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	9600000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	57500000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24100000
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6500000
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	41000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1783000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-273842000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32738000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18270000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	11000
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	112000
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	110000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	361000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1895000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	482000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	41000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-11646000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8245000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2125000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1564000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-832000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1126000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-738000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	9000
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	14127000
CY2020	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	9288000
CY2019	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	2132000
CY2021	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-209000
CY2020	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-527000
CY2019	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	21000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-45000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-610000
CY2021	cyrx	Income Tax Reconciliation Non Deductible Expense Loss On Debt Extinguishment IncomeTaxReconciliationNonDeductibleExpenseLossOnDebtExtinguishment	50817000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	913000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-7543000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2683000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	480000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Deemed Foreign Dividend Income EffectiveIncomeTaxRateReconciliationDeemedForeignDividendIncome	198000
CY2019	cyrx	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expenses Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpensesAmount	286000
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	813000
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-375000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37022000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27106000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4152000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4119000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6148000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-57507000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6875000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3837000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1222000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1077000
CY2021Q4	cyrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3471000
CY2020Q4	cyrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2740000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50793000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34878000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45885000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32913000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4908000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1965000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1650000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	529000
CY2021Q4	cyrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	3268000
CY2020Q4	cyrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	2631000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2938000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4253000
CY2021Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	651000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8507000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7413000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3599000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5448000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3599000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5448000
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-126000
CY2020	cyrx	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	528000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	1894000
CY2020	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	609000
CY2019	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	985000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	105000
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	408000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	8000
CY2020	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	112000
CY2019	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	753000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14123000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9308000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2131000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-45000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62000
CY2021	cyrx	Operating Loss Carryforwards Percent OperatingLossCarryforwardsPercent	0.80
CY2020Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53866000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1142000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3748000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4576000
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8362000
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10400000
CY2019Q1	us-gaap	Revenues Revenues	6653000
CY2019Q2	us-gaap	Revenues Revenues	8464000
CY2019Q3	us-gaap	Revenues Revenues	9583000
CY2019Q4	us-gaap	Revenues Revenues	9242000
CY2019Q1	us-gaap	Gross Profit GrossProfit	3454000
CY2019Q2	us-gaap	Gross Profit GrossProfit	4338000
CY2021Q1	us-gaap	Revenues Revenues	53284000
CY2021Q2	us-gaap	Revenues Revenues	56191000
CY2021Q3	us-gaap	Revenues Revenues	56693000
CY2021Q4	us-gaap	Revenues Revenues	56440000
CY2021Q1	us-gaap	Gross Profit GrossProfit	24550000
CY2021Q2	us-gaap	Gross Profit GrossProfit	25402000
CY2021Q3	us-gaap	Gross Profit GrossProfit	23513000
CY2021Q4	us-gaap	Gross Profit GrossProfit	23113000
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5723000
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7389000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8526000
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-262086000
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2021Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.46
CY2020Q1	us-gaap	Revenues Revenues	9774000
CY2020Q2	us-gaap	Revenues Revenues	9389000
CY2020Q3	us-gaap	Revenues Revenues	11172000
CY2020Q4	us-gaap	Revenues Revenues	48361000
CY2020Q1	us-gaap	Gross Profit GrossProfit	5258000
CY2020Q2	us-gaap	Gross Profit GrossProfit	5127000
CY2020Q3	us-gaap	Gross Profit GrossProfit	6055000
CY2020Q4	us-gaap	Gross Profit GrossProfit	19894000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3586000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5845000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10732000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9847000
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3943000
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5803000
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11418000
CY2019Q3	us-gaap	Gross Profit GrossProfit	4627000
CY2019Q4	us-gaap	Gross Profit GrossProfit	4932000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2141000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2304000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12352000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-878000
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2387000
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2528000
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12469000
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-948000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1227890

Files In Submission

Name	View Source	Status
0001410578-22-000232-index-headers.html	Edgar Link	pending
0001410578-22-000232-index.html	Edgar Link	pending
0001410578-22-000232.txt	Edgar Link	pending
0001410578-22-000232-xbrl.zip	Edgar Link	pending
cyrx-20211231.xsd	Edgar Link	pending
cyrx-20211231x10k.htm	Edgar Link	pending
cyrx-20211231x10k004.jpg	Edgar Link	pending
cyrx-20211231x10k008.jpg	Edgar Link	pending
cyrx-20211231x10k009.jpg	Edgar Link	pending
cyrx-20211231x10k010.jpg	Edgar Link	pending
cyrx-20211231x10k011.jpg	Edgar Link	pending
cyrx-20211231x10k012.jpg	Edgar Link	pending
cyrx-20211231x10k_htm.xml	Edgar Link	completed
cyrx-20211231xex21.htm	Edgar Link	pending
cyrx-20211231xex23d1.htm	Edgar Link	pending
cyrx-20211231xex31d1.htm	Edgar Link	pending
cyrx-20211231xex31d2.htm	Edgar Link	pending
cyrx-20211231xex32d1.htm	Edgar Link	pending
cyrx-20211231xex32d2.htm	Edgar Link	pending
cyrx-20211231_cal.xml	Edgar Link	unprocessable
cyrx-20211231_def.xml	Edgar Link	unprocessable
cyrx-20211231_lab.xml	Edgar Link	unprocessable
cyrx-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2021 Q4 Form 10-K Financial Statement

#000141057822000232 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2021 Q4 Form 10-K Financial Statement

#000141057822000232 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx